Clinical analysis of the value of combined detection of serum CA199 and CA50 levels in patients with pancreatic cancer

Objective: To investigate the clinical value of combined test of serum CA199 and CA50 levels in the diagnosis and prognosis of patients with pancreatic cancer. Methods: Serum levels of CA199 and CA50 in 40 cases of pancreatic cancer, 20 cases of chronic pancreatitis and 30 normal controls were detected by radioimmunoassay. Results: Serum CA199 and CA50 levels in pancreatic cancer patients were significantly higher than those in normal controls and chronic pancreatitis patients (P < 0.01). If serum CA199 and CA50 were detected simultaneously, the sensitivity, specificity and accuracy of diagnosis of pancreatic cancer could be improved. Serum CA199 and CA50 levels in cancer patients with lymph node metastasis were much higher than those without lymph node metastasis (P < 0.05). Conclusion: Serum CA199 and CA50 detected simultaneously could improve the sensitivity and accuracy in diagnosis of pancreatic cancer. The changes of serum CA199 and CA50 level were helpful to predict whether metastasis or recurrence had occurred